Enovis (NYSE:ENOV) Releases FY 2025 Earnings Guidance

Enovis (NYSE:ENOV) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 2.950-3.100 for the period, compared to the consensus earnings per share estimate of 3.180. The company issued revenue guidance of $2.2 billion-$2.3 billion, compared to the consensus revenue estimate of $2.2 billion.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reiterated a “buy” rating and set a $64.00 price target on shares of Enovis in a research report on Wednesday, April 9th.

Enovis Stock Performance

Shares of NYSE:ENOV opened at $34.17 on Thursday. The firm’s 50 day simple moving average is $35.46 and its 200 day simple moving average is $41.70. Enovis has a fifty-two week low of $29.32 and a fifty-two week high of $53.84. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -15.60 and a beta of 1.79. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.06. The company had revenue of $560.98 million for the quarter, compared to analysts’ expectations of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. As a group, sell-side analysts forecast that Enovis will post 2.79 earnings per share for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.